RxDoctor Payments Data

Carrie McInerney, APRN

Psychiatric/Mental Health · Romeoville, ILNPI 1477198513

Payments from drug & device makers

$2,911in general payments, 2019–2025

Across 118 payments — averaging $24.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sunovion Pharmaceuticals Inc.$360
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$210
  • Johnson & Johnson$190
  • Otsuka America Pharmaceutical, Inc.$126
  • Axsome Therapeutics, Inc.$103
  • plus $679 from 13 others

What the payments were for

  • Food & beverage$2,911100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,911 in reported general payments places this provider in the 85th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois

Medicare billing

Part B allowed, 2024
$35,403
Medicare patients
52
Services billed
458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$52,056
VraylarCariprazine Hcl25$34,306
Abilify MaintenaAripiprazole12$23,459
VyvanseLisdexamfetamine Dimesylate11$4,384
Desvenlafaxine Succinate ErDesvenlafaxine Succinate50$4,039
Asenapine Maleate13$2,760
Bupropion XlBupropion Hcl74$1,877
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine34$1,693
Duloxetine Hcl73$1,331
Quetiapine Fumarate26$1,131
Trazodone Hcl50$792
Fluoxetine Hcl45$758
Venlafaxine Hcl ErVenlafaxine Hcl29$640
Aripiprazole20$634
Escitalopram Oxalate27$593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$190$52,05613 claims
AbbVieVraylar$1,241$34,30625 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$126$23,45912 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$17$4,38411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 922 psychiatric/mental health providers in Illinois.

Other psychiatric/mental health in Romeoville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →